ProductProductWhat are Generics?
Actos
view photo
Generic Actos Pioglitazone Hydrochloride 15/30mg

Generic Actos is used for treating type 2 diabetes in certain patients. It is used along with diet and exercise.


Diabetes


PackagePricePer pillSavingsOrder
15mg × 30 pills$30.99$ 1.03 
15mg × 60 pills$56.99$ 0.95  $4.99
15mg × 90 pills$79.99$ 0.89  $12.98
15mg × 120 pills$97.99$ 0.82  $25.97
15mg × 180 pills$133.99$ 0.74  $51.95
PackagePricePer pillSavingsOrder
30mg × 30 pills$40.99$ 1.37 
30mg × 60 pills$75.99$ 1.27  $5.99
30mg × 90 pills$99.99$ 1.11  $22.98
30mg × 120 pills$119.95$ 1.00  $44.01
30mg × 180 pills$176.95$ 0.98  $68.99
PRODUCT DESCRIPTION Show Product Info
Search for pillsSearch for pills

TestimonialsTestimonials
Just to inform you that your package was received Friday 27 th October 14 days after dispatch , excellent service , no problems with customs , also thank you for free extra tablets , you can if you wish use this letter as a recommendation for your company , many thanks
Read more »Read more »
NewsNews
    Judge's Actos Lawsuit Order Will Make It Easier For Victims to File Claims - Virtual-Strategy Magazine
    Judge's Actos Lawsuit Order Will Make It Easier For Victims to File ClaimsVirtual-Strategy MagazineThe Actos Resource Center is the Web's largest source for information on Actos warnings, research, side effects and legal news
    Hawii Diabetes Alert: Actos diabetes medication linked to bladder cancer - InjuryBoard.com
    Hawii Diabetes Alert: Actos diabetes medication linked to bladder cancerInjuryBoard
    Nicholas J. Drakulich, Named To Plaintiffs' Steering Committee in the National ... - PR Web (press release)
    PR Web (press release)Nicholas J
    Diabetes drug Actos may pose bladder cancer risk - CBC.ca
    CBC
    Takeda's Successor Drug to Actos Fails to Win Approval - Bloomberg
    Epilepsy Research UKTakeda's Successor Drug to Actos Fails to Win ApprovalBloombergThe rejection of the drug, known chemically as alogliptin, to treat type-2 diabetes, derails Takeda President Yasuchika Hasegawa's plan for it to be a new revenue generator when its best-selling diabetes treatment Actos loses patent protection in four
Live support Online Chat


Our billing is certified by
Secure shopping certificates